SAB Biotherapeutics Inc (SABS)
3.69
-0.18
(-4.65%)
USD |
NASDAQ |
May 17, 16:00
3.69
0.00 (0.00%)
After-Hours: 20:00
SAB Biotherapeutics Total Liabilities (Quarterly): 26.64M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 26.64M |
| September 30, 2023 | 13.08M |
| June 30, 2023 | 15.73M |
| March 31, 2023 | 18.27M |
| December 31, 2022 | 19.85M |
| September 30, 2022 | 21.88M |
| Date | Value |
|---|---|
| June 30, 2022 | 22.03M |
| March 31, 2022 | 26.21M |
| December 31, 2021 | 42.59M |
| September 30, 2021 | 10.07M |
| June 30, 2021 | 15.95M |
| December 31, 2020 | 17.53M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
10.07M
Minimum
Sep 2021
42.59M
Maximum
Dec 2021
20.82M
Average
19.06M
Median
Total Liabilities (Quarterly) Benchmarks
| CEL-SCI Corp | 15.74M |
| AIM ImmunoTech Inc | 9.147M |
| IGC Pharma Inc | 2.206M |
| NovaBay Pharmaceuticals Inc | 5.197M |
| Protalix BioTherapeutics Inc | 60.04M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 83.94M |
| Shareholders Equity (Quarterly) | 57.30M |